IMCD to acquire the life science business of YCAM in South Korea and expand its footprint in the beauty and personal care markets

GlobeNewswire
2024-12-18

IMCD to acquire the life science business of YCAM in South Korea

From left to right: JaeJoong Kim, Sales Director of YCAM, Fenna van Zanten, Director M&A and member of IMCD Group Executive Committee, Munkyum Kim, CEO of YCAM, Dongjoon Lee, Managing Director of IMCD Korea, Peter Shin, Finance Director of IMCD Korea

ROTTERDAM, The Netherlands (18 December 2024) – IMCD N.V. ("IMCD" or "Company"), a global leading distribution and formulation partner of speciality chemicals and ingredients, has signed an agreement to acquire the personal care and pharmaceutical business of YCAM Corporation, a distributor based in South Korea ("YCAM").

Founded in 2010, YCAM specialises in distributing speciality ingredients for the cosmetics, personal care, and pharmaceutical markets. YCAM represents leading global suppliers and focuses on providing customers with formulatory advice and specialty ingredients through its technical team and laboratory support, helping them to stay abreast of market trends. YCAM is located in Anyang, South Korea, and generated a revenue of approximately KRW 26 billion (ca. EUR 17 million) in 2023 with 8 employees.

"This acquisition will be an important step in expanding our footprint in our beauty and personal care market and further enriches our life science portfolio," remarked Dongjoon Lee, Managing Director of IMCD South Korea. "We are excited to welcome such a dedicated and skilled team to IMCD.

 "I am convinced that YCAM’s extensive resources and knowledge can swiftly integrate into IMCD's global business model, enhancing its commercial and operational strength in South Korea's personal care and pharmaceuticals industries,” remarked Munkyum Kim, CEO of YCAM. “My team has been an invaluable asset to the company, and I believe they will have even more opportunities to develop and maximise their potential with IMCD."
 
The closing of the transaction is subject to customary (regulatory) closing conditions and is expected to take place in the second quarter of 2025.


Attached, the full press release in PDF format, the main visual and photo caption.








Attachments

  • IMCD to acquire the life science business of YCAM in South Korea
  • Photo caption - IMCD to acquire the life science business of YCAM in South Korea
  • Press release - IMCD to acquire the life science business of YCAM in South Korea

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10